Rational and Simulation-Supported Design of Inhalable RNA Nanocarrier
RatInhalRNA aims to design and optimize biocompatible siRNA nanoparticles for pulmonary delivery using a combination of DoE, MD simulations, and ML to enhance gene silencing efficacy.
Projectdetails
Introduction
The overarching goal of RatInhalRNA is to computationally predict and develop efficient formulations for pulmonary RNA therapy. New RNA formulations are imperative for clinical RNA delivery beyond the liver. The lung offers undruggable targets which could be treated with RNA therapeutics. However, approved siRNA formulations are not suited for pulmonary delivery due to instability in lung surfactant and during nebulization. Hence, it is my aim to rationally design inhalable and biocompatible polymer-based siRNA formulations for efficient siRNA delivery to the lung.
Methodology
While biomaterials are commonly optimized empirically via one-variable-at-a-time experimentation, I am the first to combine Design-of-Experiments (DoE) with Molecular Dynamics (MD) Simulations and Machine Learning (ML) to accelerate the discovery and optimization process of siRNA nanocarriers towards the metrics of gene silencing efficacy and biocompatibility at reduced wet-lab resources.
Experimental Design
In RatInhalRNA, I will synthesize amphiphilic polyspermines and will prepare siRNA-loaded nanoparticles by microfluidic assembly for experimental assessment of physico-chemical parameters as well as in vitro and in vivo gene silencing efficacy in coronavirus infection models.
Analysis
I will assess siRNA binding of the polyspermines via MD simulations and will analyze the contribution of the nanoparticle design factors on experimental and computational readout responses of the DoE.
Machine Learning Application
I will train a support vector machine for supervised ML and will generate models to identify areas of interest. Based on the predictions, I will test additional formulations to obtain a validation dataset for the assessment of the ability of the ML algorithm to identify design properties of efficient siRNA nanoparticles for pulmonary delivery.
Future Impact
RatInhalRNA will enable me to predict favorable siRNA nanoparticle characteristics in the future prior to polymer synthesis, thereby reducing experimental work and improving sustainability and animal welfare.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.000.000 |
Totale projectbegroting | € 2.000.000 |
Tijdlijn
Startdatum | 1-4-2023 |
Einddatum | 31-3-2028 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHENpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Dry Powder Formulation of RNA Nanoparticles for Inhalation and Improved Storage and Transport ConditionsRNhale aims to develop a platform technology for spray-drying RNA nanoparticles to enhance stability and target delivery, ultimately seeking licensing agreements with pharmaceutical companies. | ERC Proof of... | € 150.000 | 2022 | Details |
Kits for advanced polymer-lipid nanocarriers for targeted delivery of RNAs to cardiac and skeletal muscle cellsPOLIRNA aims to develop a versatile platform for safe and efficient RNA delivery to target multiple cell types, enhancing preclinical research in cardiac and muscle-related diseases. | ERC Proof of... | € 150.000 | 2023 | Details |
Conjugation of NAD-capped RNAs to proteins by ADP-ribosyltransferases to generate RNA therapeuticsThis project aims to develop RNAylated proteins as innovative RNA therapeutics by establishing design principles and delivery strategies to regulate cellular processes, including targeting the p53 protein. | ERC Starting... | € 1.499.162 | 2024 | Details |
Virus Inhibition by siRNA Optimized by NMRThis project aims to develop a novel class of siRNA molecules targeting SARS-CoV-2 variants using structural biology, with potential applications for other pathogenic viruses. | ERC Proof of... | € 150.000 | 2022 | Details |
Unravelling extracellular vesicle heterogeneity to inspire improved therapeutic RNA delivery systemsUNRAVEL aims to characterize extracellular vesicle subpopulations for enhanced RNA delivery, leading to the development of biomimetic synthetic RNA delivery systems to improve therapeutic applications. | ERC Consolid... | € 2.000.000 | 2025 | Details |
Dry Powder Formulation of RNA Nanoparticles for Inhalation and Improved Storage and Transport Conditions
RNhale aims to develop a platform technology for spray-drying RNA nanoparticles to enhance stability and target delivery, ultimately seeking licensing agreements with pharmaceutical companies.
Kits for advanced polymer-lipid nanocarriers for targeted delivery of RNAs to cardiac and skeletal muscle cells
POLIRNA aims to develop a versatile platform for safe and efficient RNA delivery to target multiple cell types, enhancing preclinical research in cardiac and muscle-related diseases.
Conjugation of NAD-capped RNAs to proteins by ADP-ribosyltransferases to generate RNA therapeutics
This project aims to develop RNAylated proteins as innovative RNA therapeutics by establishing design principles and delivery strategies to regulate cellular processes, including targeting the p53 protein.
Virus Inhibition by siRNA Optimized by NMR
This project aims to develop a novel class of siRNA molecules targeting SARS-CoV-2 variants using structural biology, with potential applications for other pathogenic viruses.
Unravelling extracellular vesicle heterogeneity to inspire improved therapeutic RNA delivery systems
UNRAVEL aims to characterize extracellular vesicle subpopulations for enhanced RNA delivery, leading to the development of biomimetic synthetic RNA delivery systems to improve therapeutic applications.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
ARISE - Advanced RNA Inhalation Solutions anchored in Evolved dry powder technology.RNhale's project aims to revolutionize RNA therapeutics for pulmonary diseases by developing inhalable dry powder formulations of RNA encapsulated in lipid nanoparticles. | EIC Transition | € 2.421.498 | 2025 | Details |
TraffikGene-Tx: Targeted Peptide Carriers for RNA DeliveryTraffikGene-Tx aims to develop safe, scalable peptide carriers for targeted RNA delivery, addressing genetic diseases and enhancing NAT therapies to improve patient outcomes and reduce healthcare costs. | EIC Transition | € 2.498.963 | 2023 | Details |
A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing systemThe NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases. | EIC Pathfinder | € 2.988.377 | 2023 | Details |
ARISE - Advanced RNA Inhalation Solutions anchored in Evolved dry powder technology.
RNhale's project aims to revolutionize RNA therapeutics for pulmonary diseases by developing inhalable dry powder formulations of RNA encapsulated in lipid nanoparticles.
TraffikGene-Tx: Targeted Peptide Carriers for RNA Delivery
TraffikGene-Tx aims to develop safe, scalable peptide carriers for targeted RNA delivery, addressing genetic diseases and enhancing NAT therapies to improve patient outcomes and reduce healthcare costs.
A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing system
The NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases.